CLINICAL UPDATES · SEASON 1 · EPISODE 1
Anemia of Chronic Kidney Disease
Anemia is one of the most common complications of chronic kidney disease (CKD), and it becomes more frequent as kidney function falls. This Clinical Update reviews why anemia develops in CKD, how a structured evaluation separates kidney-related anemia from other causes, and how the modern management landscape — iron therapy, erythropoiesis-stimulating agents, and newer oral agents — fits together.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.
The update
The clinical picture
Healthy kidneys sense low oxygen and release erythropoietin, the hormone that tells the bone marrow to make red blood cells. In CKD that signal weakens. At the same time, inflammation raises hepcidin, a hormone that traps iron inside storage cells and blocks its absorption from food, so even patients with adequate iron stores may not be able to use it. The result is a normocytic anemia that tracks with CKD stage: uncommon in early disease, very common by the time patients reach dialysis. Blood loss from frequent testing and dialysis circuits, shortened red cell survival, and nutritional deficiencies add to the picture.
The current landscape
The modern landscape starts with iron. Guidelines such as KDIGO's anemia guideline frame iron status with ferritin and transferrin saturation, and intravenous iron is used widely in dialysis patients while oral iron may suffice earlier. Erythropoiesis-stimulating agents (ESAs) remain a mainstay for patients whose hemoglobin stays low after iron is corrected, dosed to relieve symptoms and reduce transfusions rather than to normalise hemoglobin. A newer class, the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), stimulates the body's own erythropoietin production and improves iron mobilisation; these oral agents are approved for dialysis populations in a number of countries, with regulatory status varying by region.
In practice
Evaluation begins by confirming anemia and reviewing the trend, then checking iron studies, reticulocyte count, vitamin B12 and folate, and looking for bleeding or inflammation that would point elsewhere — CKD should not become a diagnosis of exclusion by default. Iron deficiency is corrected first and iron status rechecked before labelling anemia refractory. When an ESA is used, hemoglobin is monitored regularly and the dose adjusted gradually, because rapid rises and high targets have been linked to cardiovascular harm in trials. Transfusion is kept for symptomatic patients, those with acute blood loss, and selected pre-transplant situations, weighing the sensitisation risk that transfusion carries for future transplant candidates.
When to escalate
Escalate promptly when anemia is disproportionate to the CKD stage, appears suddenly, or comes with features that do not fit — weight loss, visible bleeding, or abnormal white cell or platelet counts all warrant a broader workup, including hematology input. New chest pain, breathlessness, or signs of heart failure in a severely anemic patient need same-day assessment. Loss of response to a previously effective ESA dose is another red flag: it usually signals iron deficiency, infection, or inflammation, but occasionally points to rarer marrow problems that need specialist evaluation.
Common questions
Why does kidney disease cause anemia?
The kidneys produce erythropoietin, the hormone that drives red blood cell production. As kidney function declines, less hormone is made. CKD also raises hepcidin, which locks iron away, so the marrow lacks both the signal and the raw material to make red cells.
What blood tests are used to evaluate anemia in CKD?
A full blood count with hemoglobin trend, iron studies (ferritin and transferrin saturation), reticulocyte count, and vitamin B12 and folate levels form the core panel. Kidney function, inflammatory markers, and a review for blood loss complete the usual workup.
What is the difference between iron therapy and an ESA?
Iron therapy replaces a missing raw material and is corrected first. An erythropoiesis-stimulating agent (ESA) replaces the missing hormone signal, prompting the marrow to produce more red cells. Many patients need both, in sequence, guided by regular blood tests.
Why not simply aim for a normal hemoglobin level?
Large trials found that pushing hemoglobin to normal with ESAs increased strokes and cardiovascular events without improving survival. Modern practice targets a level that relieves symptoms and avoids transfusions, individualised to the patient, rather than a normal laboratory value.
More in Chronic Kidney Disease Care
Related
Related reading
Sources
- Clinical Practice Guideline for Anemia in Chronic Kidney Disease (KDIGO)
- Anemia (MedlinePlus, US National Library of Medicine)
- Chronic Kidney Disease (CKD) (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- CKD Evaluation and Management Guideline (KDIGO)
This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Treatment choices in anemia of CKD depend on dialysis status, iron indices, and cardiovascular history; dosing decisions belong with the treating team.